IMpower010 & Atezolizumab: The trial has cemented the significance of atezolizumab in the potential treatment options for lung cancer, especially as an adjuvant in non-small cell lung cancer (NSCLC). Debate & Discourse: While promising, the broadened approval and usage of atezolizumab have sparked meaningful debate regarding its universal applicability and effectiveness. Unbiased Presentation: The oncological community must remain vigilant, ensuring that data and results are presented without bias, offering patients and practitioners clear insights into potential treatment modalities. In the vast realm of oncology, lung cancer remains a predominant concern and focus of rigorous scientific research. At the forefront of…
Author: admin
Ryan D. Cassaday,MD- Physician-Fred Hutch Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the debate between inotuzumab and blinatumumab to choosing between seat belts and airbags, highlighting his belief that both treatments have significant roles to play. Dr. Cassaday focuses on presenting data supporting inotuzumab, specifically in the context of older adults with pH-negative B cell acute lymphoblastic leukemia (ALL). He discusses studies from MD Anderson and the German Cooperative Group that showcase the effectiveness of inotuzumab in inducing morphologic remission and achieving favorable survival curves, despite challenges such as toxicity. REGISTER NOW TO…
Anjali Advani, MD- Hematology and Medical Oncology- Cleveland Clinic Anjali Advani, MD, begins her talk by expressing gratitude for the invitation to speak. She proceeds to discuss the integration of blinatumomab into upfront therapy for acute lymphoblastic leukemia (ALL). Dr. Advani explains that blinatumomab, a bispecific antibody engaging CD3 and CD19, effectively induces T-cell proliferation and apoptosis of leukemia cells. She emphasizes blinatumomab’s advantages, including its lack of attached chemotherapy, reduced risk of complications, and potential immune effects. Dr. Advani discusses ongoing efforts to refine blinatumomab’s administration and dosage for optimal patient outcomes. REGISTER NOW TO JOIN US AT THESE…
Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Aaron Logan, MD PhD, conveyed his gratitude to the event organizers and acknowledged the valuable input of different perspectives at the meeting. He highlighted the critical role of assessing minimal residual disease (MRD) in leukemia treatment strategies. Drawing on data from various studies, Dr. Logan underscored how MRD presence or absence can accurately predict survival outcomes in patients undergoing therapy for leukemia. However, he also acknowledged the limitations of MRD assessments, as they don’t always perfectly predict relapse or remission. He discussed the importance of precise MRD…
Jalen Patel, MD – City of Hopeaugust 21, 2023Drawing from data provided by ASCO and Friends of Cancer Research, the study endeavors to characterize the eligibility criteria employed in advanced prostate cancer investigations. The primary objective centers on ensuring that the clinical trial parameters accurately reflect the broader population.The classification involves three distinct categories: exclusion, conditional inclusion, and instances where criteria were not reported. Upon scrutinizing the criteria of interest, the analysis reveals a predominant tendency among trials to exclude individuals with brain metastases, HIV, hepatitis B and C, as well as concurrent malignancies. The subsequent breakdown of four figures…
Akasha Dukkipati, MD at City of Hope August 21, 2023 Akasha Dukkipati, MD at City of Hope, conducted an analysis of urothelial cancer studies spanning a decade, from 2012 to 2022. The aim was to scrutinize eligibility criteria due to concerns raised by a collaborative statement from ASCO and Friends of Cancer Research. The joint statement underscored the underrepresentation of certain clinical attributes resulting from overly stringent eligibility standards in clinical trials. The physician’s team specifically focused on advanced urothelial cancer studies, examining four primary exclusion factors: concurrent malignancies, brain metastases, hepatitis B and C infections, and HIV. Their findings…
Mark Litzow, MD- Hematologist, Oncologist, Palliative Care Specialist- Mayo Clinic In a presentation delivered by Mark Litzow, MD, the speaker expresses gratitude for the invitation and acknowledges the organizers. The speaker humorously remarks that they are unsure who needs transplants nowadays. They express their intention to address the question of who needs transplantation in the first remission (CR1) and highlight the importance of relapse and its relation to transplant outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register –…
Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX – Section Chief, Leukemia/Lymphoma, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX Branko Cuglievan, MD, expresses gratitude for being invited to an adult conference to discuss pediatric data and challenges. He addresses the differences in age distribution between acute myeloid leukemia (AML) and pediatric leukemias. Dr. Cuglievan emphasizes the lower incidence of pediatric AML cases and the struggle to enroll sufficient patients for studies due to the dispersed…
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, expresses gratitude for the invitation to speak at the meeting and discusses the genomic classification of leukemia, particularly focusing on B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL). He covers three main areas: B-ALL genomic classification, its implications for diagnosis and risk assessment, and recent unpublished data on T-ALL classification. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered by Elias Jabbour, MD, centers around the treatment paradigm for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), proposing a shift from traditional chemotherapy to tyrosine kinase inhibitors (TKIs) and immunotherapy. Dr. Jabbour discusses the historical use of allogeneic stem cell transplantation and its limitations. The presentation delves into data from MD Anderson and other studies, emphasizing the challenge of achieving high survival rates. The concept of complete molecular remission (CMR) is underscored, with an emphasis on early molecular response deepening.…
Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock, MD, addresses optimizing outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Dr. Stock expresses gratitude for the opportunity and highlights the importance of such meetings, drawing from her own experience when starting her career. She discusses the positive changes in patient outcomes, particularly emphasizing minimal residual disease (MRD) eradication as a key goal. The importance of blending new therapies with older approaches and using less aggressive treatment for older patients and AYAs is mentioned. Dr. Stock…
Marina Konopleva, M.D., Ph.D.- Professor, Department of Oncology (Medical Oncology) Professor, Department of Molecular Pharmacology- Albert Einstein College of Medicine In this presentation by Marina Konopleva, MD, she covers the resistance mechanisms and potential combination strategies related to venetoclax, an AML (acute myeloid leukemia) treatment. Despite overlapping slides, she delves into the topic, shedding light on resistance challenges. Konopleva elaborates on the mechanism of action, targeting BCL-2, and its interaction with mitochondrial proteins. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/…
Tapan Kadia, MD- Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX In this presentation Tapan Kadia, MD discusses the challenge of high relapse rates despite achieving complete remissions with newer therapies. Historical attempts at maintenance therapy are reviewed, with improvements seen in relapse-free survival but not overall survival. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Dr. Kadia highlights the success of oral hypomethylating…
Hetty Carraway, MD- Hematology and Medical Oncology- Cleveland Clinic Hetty Carraway, MD, delivers a comprehensive discussion on immune-based and novel strategies to enhance outcomes for patients with myelodysplastic syndromes (MDS). The focus lies on unraveling the intricate relationship between the immune system and MDS pathogenesis, exploring immune interventions like immune checkpoint inhibitors (ICIs), and addressing challenges related to immune manipulation, mutational profiles, and the microenvironment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…
Andrew Artz MD- Hematologist-Oncologist- City Of Hope Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the topic’s extensive coverage. Playfully, he considers sharing random pictures or dinner plans but proceeds to discuss his presentation’s content. He highlights the increasing use of allogeneic transplants, especially for older patients and those in first remission, attributing this rise to novel therapies. Dr. Artz emphasizes the challenge of relapse and the need to balance it against transplant-related toxicities. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…
Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) Yasmin Abaza, MD discusses advancements and challenges in the treatment of Acute Myeloid Leukemia (AML) using immunotherapies. Over the past five decades, outcomes for AML patients have improved, but long-term survival rates remain low, highlighting the need for new treatment options. Allogeneic stem cell transplantation is a potent immunotherapy for AML, particularly in patients with intermediate or adverse risk disease. The transplantation’s effectiveness lies in the donor T cell’s ability to target and destroy leukemia cells through interactions with AML cells’ molecular markers. Despite its benefits, this approach is associated with graft-versus-host…
Dr. Ghassan Abu Alfa, MD with Memorial Sloan Kettering Cancer Center in New York, provides an update on the key findings of the Himalaya clinical trial. The trial, a phase 3 study, investigated the combination of darvalumab and tremelumab for patients with intractable hepatocellular carcinoma. The study involved a phase 3 clinical trial, comparing the combination therapy to sorafenib, the prevailing standard care at that time and widely used globally. The primary focus was on enhancing survival outcomes with the combination of Dervalumab and Tremelumab versus Sorafenib. Notably, the median overall survival was approximately 16.5 months for the combination therapy…
Dr. Jack West,MD an associate professor in medical oncology at City of Hope Comprehensive Cancer Center in Los Angeles, discussed a recent publication in the Annals of Oncology regarding the IMpower010 trial. The trial focused on the adjuvant use of atezolizumab and was initially presented by Dr. Heather Wakely and colleagues at ASCO 2021. The trial showed a statistically significant improvement in disease-free survival for patients with stage 2 to 3a resected non-small cell lung cancer and PD-L1 of 1% or higher who received adjuvant atezolizumab compared to placebo. While the trial demonstrated benefits in disease-free survival, further analysis reveals…
Naval Daver MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval Daver, MD expresses uncertainty and discusses the need for personalized treatment strategies. He mentions starting with a metaphor about eggs and ice cream preferences. They highlight the lack of data on triple therapy and the importance of considering individual differences. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The talk shifts to triple…
Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center The presentation discusses the management and treatment strategies for patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) receiving hypomethylating agents (HMA) in combination with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Brian Andrew Jonas, M.D., Ph.D. discusses various aspects of this treatment approach, including dosing regimens, response…
Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine The presentation discusses various aspects of treatment strategies for newly diagnosed acute myeloid leukemia (AML), focusing on optimizing therapy approaches and providing practical insights for healthcare professionals. It delves into considerations for patients who are not suitable for intensive chemotherapy, explores the use of different approved or accessible agents, and emphasizes the importance of achieving transfusion independence and improved quality of life for AML patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…
In the dynamic world of oncology, chemotherapy stands as a beacon of hope for many battling the formidable challenge of cancer. When diagnosed with cancer, patients are presented with a spectrum of treatment modalities, and one of the most crucial decisions revolves around when and how to administer chemotherapy. Amidst the plethora of choices, one term has steadily gained prominence: neoadjuvant chemotherapy. But what is neoadjuvant chemotherapy? And how does it distinguish itself from other treatment strategies? What is Neoadjuvant Chemotherapy? Stepping into the world of oncology, terms and treatments can often feel overwhelming. Amidst the myriad of terminologies, neoadjuvant…
Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Emerging as a beacon of hope in the realm of acute myeloid leukemia (AML) treatment, a new frontier is being forged through the synergistic power of innovative drug combinations. By intertwining the potency of IDH inhibitors like ivosidenib and enasidenib with hypomethylating agents and the precision of venetoclax, a novel therapeutic approach is taking center stage. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…
Eytan M. Stein, MD – Hematologist-Oncologist – Memorial Sloan Kettering Cancer Center Discover the cutting-edge landscape of acute myeloid leukemia (AML) treatment with a focus on Revumenib and Ziftomenib, two promising menin inhibitors. Delving into the realm of AML therapy, this discussion navigates through the potential roles of Revumenib and Ziftomenib in treating relapsed and refractory cases, particularly among patients with KMT2A rearrangements and NPM1 mutations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US…
Presented By: Brian Warnecke, DO – UC-Irvine Hematology Oncology Fellow, PGY-5 Date: August 12, 2023The presentation titled “Multi-omic Characterization of RCC1 Expression and its Association with Molecular Alterations, Immune Phenotypes, and Cancer Outcomes,” conducted by Brian Warnecke, D.O., a UC-Irvine Hematology Oncology Fellow in his PGY-5, unveils a comprehensive investigation into the multifaceted role of Regulator of Chromosome Condensation 1 (RCC1) in cancer development and progression. Collaboratively led by principal investigators Dr. Mohammed Al Hallak (Karmanos), Dr. Asfar Azmi (Karmanos), and Dr. Misako Nagasaka (UC Irvine), this research endeavor delves into the intricate interplay between RCC1 expression, molecular alterations, immune…
Presented By: Dalia Kaakour, MD – University of California, Irvine Date: Aug 12, 2023 In the realm of oncology and immunotherapy, the investigation into the safety and efficacy of immune checkpoint inhibitors (CPIs) takes a step forward with an insightful study by Dr. Dalia Kaakour, MD, MPH, from the University of California, Irvine’s Department of Medicine Division of Hematology and Oncology Fellowship Program. With an absence of any disclosures, this study delves into the realm of immune-related adverse events (irAEs) in patients afflicted by both solid tumors and advanced chronic kidney disease (CKD) who are undergoing treatment with CPIs. Traditionally,…
Presented By: Shirin Attarian, MD Date Aug 12, 2023 In the realm of oncology, Head and Neck Cancer stands as a significant challenge, both in terms of its prevalence and the intricacies surrounding its diagnosis and treatment. This complex and diverse set of malignancies affects millions across the globe each year, making it the seventh most common cancer worldwide. Amid the countless battles against this formidable adversary, the insights of medical professionals like Dr. Shirin Attarian have proven invaluable. Dr. Attarian’s meticulous review of Head and Neck Cancer reveals a landscape of statistics that underscore the urgency of continued research…
Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward Per, MD, MS emphasizes the need to unravel the intricacies of both primary and secondary resistance mechanisms associated with FLT3 inhibitors, highlighting their role in AML management. Discussions revolve around the potential of these inhibitors to target FLT3 mutations, while also addressing challenges such as polyclonality and the selection of resistant clones. The importance of achieving optimal disease response is underscored, with an emphasis on utilizing minimal residual disease (MRD) testing to guide treatment decisions and enhance patient outcomes. REGISTER…
Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. In his compelling presentation, Farhad Ravandi, MD, a distinguished medical professional in the field of oncology, delves into the critical significance of minimal residual disease (MRD) assessment in the realm of acute myeloid leukemia (AML) treatment. As an accomplished hematologist, Dr. Ravandi brings his extensive expertise to the forefront, elucidating how achieving complete morphological remission is a pivotal determinant in long-term survival for AML patients. REGISTER NOW…
Refresh URL Changing Content
Spotlight on Oncology: Exploring the Latest Advances in Lung Cancer Research Date: August 12, 2023 Speaker: Sai-Hong Ignatius Ou, MD PhD Welcome to the 2023 MAOSC Spotlight on Oncology, a dynamic event that brings together leading minds in the field of lung cancer research to discuss groundbreaking developments and insights. This year’s event focuses on the latest advancements in lung cancer treatment, with a special emphasis on the management of lung cancer through various stages. At the helm of this enlightening discussion is the esteemed Dr. Sai-Hong Ignatius Ou, MD PhD. Dr. Ou is a distinguished Health Science Clinical Professor…
teste desc
Updates in Lymphoma: Advancements in Treatment Strategies Date: August 12, 2023Presenter: Elizabeth Brem, MD (Clinical Associate Professor) In the ever-evolving landscape of oncology, particularly in the field of lymphoma treatment, significant strides have been made to improve patient outcomes and quality of life. Dr. Elizabeth Brem, a prominent figure in the field, delivered a comprehensive presentation on the recent updates in lymphoma treatment during the recent event. Dr. Brem is a Clinical Associate Professor renowned for her expertise and contributions to the field. Disclosures: Dr. Elizabeth Brem is associated with several pharmaceutical and biotech companies, reflecting her active engagement in…
Interview with Pankit Vachhani, MD Hematology Oncology- UAB Medicine Timestamps: 0:00:09 What is the objective of this study on indolent systemic mastocytosis (ISM)?0:00:50 How were patients with ISM randomized in this study, and what were the treatment groups?0:01:48 What was the primary endpoint measured in this study, and how was it assessed?0:02:20 What were the secondary endpoints evaluated in this study?0:03:19 What were the results regarding the mean change in total symptom score (TSS) between the avapritinib and placebo groups?0:04:17 How did avapritinib treatment impact serum tryptase levels in patients with ISM?0:05:02 Were there any notable differences in adverse events…
Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join us on a journey to the forefront of Acute Myeloid Leukemia (AML) treatment, guided by the expertise of Amir T. Fathi MD. In the dynamic landscape of 2023, Dr. Fathi’s insights illuminate the remarkable progress being made, specifically within the realm of IDH 1/2-mutant AML cases. This transformative approach integrates cutting-edge molecular insights and targeted therapies, revolutionizing the trajectory of AML care. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL…
Harry Paul Erba, MD Professor of Medicine Member of the Duke Cancer Institute This content features Harry Paul Erba, MD, who discusses the optimization of frontline therapy for FLT3 mutated AML patients, focusing on quizartinib’s impact. Dr. Erba explains the pivotal role of FLT3 receptor tyrosine kinase in hematopoiesis and its connection to AML blast. He details the variations in FLT3 mutations, encompassing internal tandem duplication (ITD) and TKD mutations, elucidating their distinct prognostic implications. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. In a dynamic presentation at the recent event, Joseph D. Khoury, MD delved into the intricate realm of Acute Myeloid Leukemia (AML), shedding light on genetic advancements, diagnostic nuances, and promising targeted therapies. The engaging discourse began with gratitude for the invitation and San Diego’s delightful weather. Coming from varied backgrounds like Houston, Texas, and even Nebraska, the speaker emphasized their unique vantage point straddling different locales. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online…
The “MOASC SPOTLIGHT ON ONCOLOGY – GU ASCO UPDATES” seminar, led by Dr. Nataliya Mar, Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, August 12, 2023 This discussion marked a significant milestone in the field of genitourinary oncology. Dr. Mar’s insightful presentation delved into various scenarios, revealing the complex landscape of oncology care and the advancements in treatment strategies. At the outset, Dr. Mar disclosed her affiliations with leading pharmaceutical companies, including Seattle Genetics, Aveo, Eisai, Tempus, and Merck, which underscores the relevance of her insights and findings in the context of emerging therapies…
Pancreatic Cancer Updates – Insights from Vincent Chung, MDDiscover the latest advancements in the field of pancreatic cancer through an enlightening presentation by Dr. Vincent Chung, a distinguished figure in oncology and a consultant for Perthera. Delve into the comprehensive exploration of Pancreatic Cancer, its challenges, and the transformative approaches to treatment. This event, held on August 12, 2023, at the MOASC / UCI Spotlight on Oncology, presents crucial updates that could revolutionize the landscape of pancreatic cancer care.Understanding the Scope of the ProblemWith the unfortunate distinction of having the worst survival rates among solid tumors, pancreatic cancer poses a…
Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center Discover the latest advancements in the field of Hepatobiliary Cancers in this comprehensive session titled “Hepatobiliary Cancers Therapeutic Updates” featuring the esteemed Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center, Dr. El-Khoueiry brings his expertise to illuminate the cutting-edge developments in the treatment of hepatobiliary cancers.This session delves into critical topics that are reshaping the landscape of hepatobiliary cancer therapies. The intricate…
MOASC – Spotlight on Oncology Colorectal Cancer AbstractsDate: August 12, 2023Location: Huntington Beach, CAPresenter: Jason A. Zell, DO, MPHPosition: Professor, Vice Chief of Academic AffairsDivision of Hematology/Oncology, Dept. of MedicineUniversity of California Irvine In this spotlight session on oncology, the focus was on Colorectal Cancer (CRC) abstracts, with special attention given to the latest advancements and research findings. The presenter, Dr. Jason A. Zell, a distinguished figure in the field, holds the position of Professor and Vice Chief of Academic Affairs within the Division of Hematology/Oncology at the University of California Irvine. Abstracts were presented, shedding light on significant studies…
Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of Medicine, UCI Health, presented updates on breast cancer research during the MOASC (Medical Oncology Association of Southern California) Spotlight On Oncology. Here’s a breakdown of the key topics discussed: Presenter Disclosures: Dr. Lavasani’s disclosures include associations with Daichii Sankyo, Seagen, Sermonix, and Astrazeneca for honorarium, institutional research funding, consultation, and speaker engagements. Outline: Hormone Positive Breast Cancer: Early Stage (NATALEE) Metastatic Breast Cancer: SONIA HER2+ Breast Cancer: PHERGain (Cortes et al.) Key Highlights: Hormone Positive Breast Cancer – NATALEE Study:…
In the ever-evolving world of oncology, there is always a beacon of hope on the horizon. The latest such promise comes in the form of a drug known as Sacituzumab Govitecan. This compound, while complex in name, is pioneering some of the latest advancements in cancer treatments, particularly in the realm of Triple-Negative Breast Cancer (TNBC). What is Sacituzumab Govitecan? Every drug, from the over-the-counter solutions to groundbreaking cancer treatments, has a story to tell, often starting with its name. Sacituzumab Govitecan isn’t merely a jumble of syllables. It’s a name derived from the drug’s intricate nature and function. While…
Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Sanam Loghavi is an accomplished pathologist known for her expertise in the field of hematopathology and her contributions to the diagnosis and understanding of various hematologic malignancies, including acute myeloid leukemia (AML). Her work focuses on unraveling the molecular intricacies of AML and other blood disorders to enhance patient care through personalized treatment strategies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…
For those with an interest in the management of acute myeloid leukemia, the conference provided a unique and valuable platform. Attendees commended the insightful talks and the lively debates that ensued, offering a wealth of perspectives and research ideas. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The sentiment expressed was overwhelmingly positive, with participants applauding the conference’s exceptional speakers, engaged audience, interactive format, and the prospect of forging new…
The discussion revolves around the complexities of Blinatumomab treatment for leukemia, with experts debating the reasons behind the partial clinical hold on cooperative group studies, concerns about combining treatments concurrently, and the potential impact of reducing chemotherapy intensity. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Topics also include the risk of CNS relapses, the significance of IT chemotherapy, and the emergence of CD19-negative relapses with Blinatumomab. The experts emphasize…